Skip to main content

Standard Biotools Inc.

LAB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001162194

No open-market purchases or sales by Standard Biotools Inc. insiders were filed in the last 90 days; 143 institutions reported holding it in 13F filings for Q2 2026, worth $243.6M in total; Viking Global Investors is the only superinvestor holding it.

Holders of 5% or more of LAB

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Standard Biotools Inc., largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of LAB
HolderLatest formStakeChangeFirst filedLatest filingFiling
Casdin Capital, LLC13D/A21.60%80.9M shares–Mar 4, 20251 filingMar 4, 2025SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

1 Schedule 13D or 13G filing on Standard Biotools Inc., newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on LAB
Filed (ET)FilerFormStakeChangeEvent dateFiling
Mar 4, 20257:46 PM ETCasdin Capital, LLCand 5 others13D/A21.60%80.9M shares–Feb 28, 2025SEC

Form 144: proposed insider sales

Notices from officers, directors and other affiliates planning to sell Standard Biotools Inc. shares.

No Form 144 notices for Standard Biotools Inc. are on file.